<s id="wsj_1938.1"> 29
1 	 0 	 N/N 	 1 	 Ltd. Ciba-Geigy
1 	 5 	 (S[dcl]\NP)/S[dcl] 	 1 	 Ltd. said
4 	 3 	 N/N 	 1 	 Corp. Chiron
4 	 5 	 (S[dcl]\NP)/S[dcl] 	 1 	 Corp. said
6 	 7 	 (S[dcl]\NP)/NP 	 1 	 they extended
7 	 5 	 (S[dcl]\NP)/S[dcl] 	 2 	 extended said
7 	 26 	 ((S\NP)\(S\NP))/NP 	 2 	 extended to
9 	 7 	 (S[dcl]\NP)/NP 	 2 	 offer extended
9 	 8 	 NP[nb]/N 	 1 	 offer their
9 	 10 	 (NP\NP)/NP 	 1 	 offer for
9 	 15 	 (S[pss]\NP)/PP 	 1 	 offer valued <XB>
13 	 10 	 (NP\NP)/NP 	 2 	 Inc. for
13 	 11 	 N/N 	 1 	 Inc. Connaught
13 	 12 	 N/N 	 1 	 Inc. BioSciences
16 	 15 	 (S[pss]\NP)/PP 	 2 	 at valued
18 	 17 	 (N/N)/(N/N) 	 2 	 million 866
20 	 16 	 PP/NP 	 1 	 dollars at
20 	 18 	 N/N 	 1 	 dollars million
20 	 19 	 N/N 	 1 	 dollars Canadian
20 	 21 	 (NP\NP)/NP 	 1 	 dollars -LRB-
22 	 21 	 (NP\NP)/NP 	 2 	 US$ -LRB-
24 	 22 	 N/N[num] 	 1 	 million US$
24 	 23 	 N/N 	 1 	 million 736
27 	 26 	 ((S\NP)\(S\NP))/NP 	 3 	 Oct. to
28 	 27 	 N/N[num] 	 1 	 27 Oct.
<\s>
<s id="wsj_1938.2"> 31
1 	 0 	 NP[nb]/N 	 1 	 companies The
1 	 3 	 (S[dcl]\NP)/S[dcl] 	 1 	 companies said
3 	 2 	 (S\NP)/(S\NP) 	 2 	 said earlier
4 	 5 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 they did
4 	 7 	 (S[b]\NP)/(S[to]\NP) 	 1 	 they want <XB>
4 	 9 	 (S[b]\NP)/NP 	 1 	 they raise <XB>
4 	 13 	 (S[b]\NP)/NP 	 1 	 they match <XB>
5 	 3 	 (S[dcl]\NP)/S[dcl] 	 2 	 did said
5 	 6 	 (S\NP)\(S\NP) 	 2 	 did n't
7 	 5 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 want did
8 	 7 	 (S[b]\NP)/(S[to]\NP) 	 2 	 to want
9 	 8 	 (S[to]\NP)/(S[b]\NP) 	 2 	 raise to
11 	 9 	 (S[b]\NP)/NP 	 2 	 offer raise
11 	 10 	 NP[nb]/N 	 1 	 offer their
13 	 12 	 (S[to]\NP)/(S[b]\NP) 	 2 	 match to
16 	 13 	 (S[b]\NP)/NP 	 2 	 bid match
16 	 14 	 NP[nb]/N 	 1 	 bid a
16 	 15 	 N/N 	 1 	 bid rival
16 	 17 	 (NP\NP)/NP 	 1 	 bid by
16 	 21 	 (NP\NP)/NP 	 1 	 bid of
20 	 17 	 (NP\NP)/NP 	 2 	 S.A. by
20 	 18 	 N/N 	 1 	 S.A. Institut
20 	 19 	 N/N 	 1 	 S.A. Merieux
22 	 21 	 (NP\NP)/NP 	 2 	 C$ of
22 	 24 	 (NP\NP)/N 	 1 	 C$ a
23 	 22 	 N/N[num] 	 1 	 37 C$
25 	 24 	 (NP\NP)/N 	 2 	 share a
28 	 21 	 (NP\NP)/NP 	 2 	 C$ of
30 	 28 	 N/N[num] 	 1 	 million C$
30 	 29 	 N/N 	 1 	 million 942
<\s>
<s id="wsj_1938.3"> 21
1 	 2 	 (S[dcl]\NP)/S[dcl] 	 1 	 they said
2 	 0 	 S/S 	 1 	 said But
5 	 4 	 (N/N)/N[num] 	 2 	 30-a-share C$
6 	 3 	 NP[nb]/N 	 1 	 bid the
6 	 4 	 (N/N)/N[num] 	 1 	 bid C$
6 	 8 	 (NP\NP)/(S[dcl]\NP) 	 1 	 bid which
6 	 9 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 bid was <XB>
6 	 10 	 (S[adj]\NP)/(S[to]\NP) 	 1 	 bid due <XB>
6 	 15 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 bid may
6 	 18 	 S[pss]\NP 	 1 	 bid extended <XB>
6 	 20 	 S[pss]\NP 	 1 	 bid varied <XU>
9 	 8 	 (NP\NP)/(S[dcl]\NP) 	 2 	 was which
10 	 9 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 due was
11 	 10 	 (S[adj]\NP)/(S[to]\NP) 	 2 	 to due
12 	 11 	 (S[to]\NP)/(S[b]\NP) 	 2 	 expire to
12 	 13 	 (S\NP)\(S\NP) 	 2 	 expire Monday
15 	 2 	 (S[dcl]\NP)/S[dcl] 	 2 	 may said
15 	 16 	 (S\NP)\(S\NP) 	 2 	 may still
17 	 15 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 be may
18 	 17 	 (S[b]\NP)/(S[pss]\NP) 	 2 	 extended be
20 	 17 	 (S[b]\NP)/(S[pss]\NP) 	 2 	 varied be
<\s>
<s id="wsj_1938.4"> 18
0 	 11 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 Merieux is
0 	 12 	 (S[adj]\NP)/PP 	 1 	 Merieux 51%-held <XB>
4 	 2 	 NP[nb]/N 	 1 	 manufacturer a
4 	 3 	 N/N 	 1 	 manufacturer vaccine
4 	 5 	 S[pss]\NP 	 1 	 manufacturer based <XB>
4 	 11 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 manufacturer is
4 	 12 	 (S[adj]\NP)/PP 	 1 	 manufacturer 51%-held <XB>
5 	 6 	 ((S\NP)\(S\NP))/NP 	 2 	 based in
7 	 6 	 ((S\NP)\(S\NP))/NP 	 3 	 Lyon in
9 	 6 	 ((S\NP)\(S\NP))/NP 	 3 	 France in
12 	 11 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 51%-held is
13 	 12 	 (S[adj]\NP)/PP 	 2 	 by 51%-held
17 	 13 	 PP/NP 	 1 	 S.A by
17 	 14 	 N/N 	 1 	 S.A French
17 	 15 	 N/N 	 1 	 S.A state-owned
17 	 16 	 N/N 	 1 	 S.A Rhone-Poulenc
<\s>
<s id="wsj_1938.5"> 11
0 	 1 	 (S[dcl]\NP)/NP 	 1 	 Ciba-Geigy is
5 	 1 	 (S[dcl]\NP)/NP 	 2 	 concern is
5 	 2 	 NP[nb]/N 	 1 	 concern a
5 	 3 	 N/N 	 1 	 concern major
5 	 4 	 N/N 	 1 	 concern pharmaceutical
5 	 6 	 S[pss]\NP 	 1 	 concern based <XB>
6 	 7 	 ((S\NP)\(S\NP))/NP 	 2 	 based in
8 	 7 	 ((S\NP)\(S\NP))/NP 	 3 	 Basel in
10 	 7 	 ((S\NP)\(S\NP))/NP 	 3 	 Switzerland in
<\s>
<s id="wsj_1938.6"> 12
0 	 6 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 Chiron is
0 	 7 	 S[pss]\NP 	 1 	 Chiron based <XB>
4 	 2 	 NP[nb]/N 	 1 	 concern another
4 	 3 	 N/N 	 1 	 concern pharmaceutical
4 	 6 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 concern is
4 	 7 	 S[pss]\NP 	 1 	 concern based <XB>
7 	 6 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 based is
7 	 8 	 ((S\NP)\(S\NP))/NP 	 2 	 based in
9 	 8 	 ((S\NP)\(S\NP))/NP 	 3 	 Emeryville in
11 	 8 	 ((S\NP)\(S\NP))/NP 	 3 	 Calif in
<\s>
<s id="wsj_1938.7"> 9
0 	 1 	 (S[dcl]\NP)/NP 	 1 	 Connaught is
4 	 1 	 (S[dcl]\NP)/NP 	 2 	 research is
4 	 2 	 NP[nb]/N 	 1 	 research a
4 	 3 	 N/N 	 1 	 research biotechnology
8 	 1 	 (S[dcl]\NP)/NP 	 2 	 concern is
8 	 2 	 NP[nb]/N 	 1 	 concern a
8 	 3 	 N/N 	 1 	 concern biotechnology
8 	 6 	 N/N 	 1 	 concern vaccine
8 	 7 	 N/N 	 1 	 concern manufacturing
<\s>
<s id="wsj_1938.8"> 37
1 	 0 	 N/N 	 1 	 Merieux Institut
1 	 2 	 (NP[nb]/N)\NP 	 2 	 Merieux 's
3 	 2 	 (NP[nb]/N)\NP 	 1 	 bid 's
3 	 4 	 (NP\NP)/NP 	 1 	 bid for
3 	 7 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 bid has
3 	 8 	 S[pt]\NP 	 1 	 bid run <XB>
6 	 4 	 (NP\NP)/NP 	 2 	 Connaught for
6 	 5 	 N/N 	 1 	 Connaught Toronto-based
8 	 7 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 run has
8 	 9 	 ((S\NP)\(S\NP))/NP 	 2 	 run into
10 	 9 	 ((S\NP)\(S\NP))/NP 	 3 	 problems into
10 	 11 	 (NP\NP)/NP 	 1 	 problems with
14 	 11 	 (NP\NP)/NP 	 2 	 government with
14 	 12 	 NP[nb]/N 	 1 	 government the
14 	 13 	 N/N 	 1 	 government Canadian
14 	 16 	 (NP\NP)/(S[dcl]\NP) 	 1 	 government which
14 	 17 	 ((S[dcl]\NP)/S[em])/NP 	 1 	 government told <XB>
17 	 16 	 (NP\NP)/(S[dcl]\NP) 	 2 	 told which
17 	 20 	 (S\NP)\(S\NP) 	 2 	 told week
18 	 17 	 ((S[dcl]\NP)/S[em])/NP 	 3 	 Merieux told
20 	 19 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 week last
21 	 17 	 ((S[dcl]\NP)/S[em])/NP 	 2 	 that told
22 	 23 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 it was
22 	 25 	 (S[pss]\NP)/S[em] 	 1 	 it convinced <XB>
23 	 21 	 S[em]/S[dcl] 	 1 	 was that
23 	 24 	 (S\NP)\(S\NP) 	 2 	 was n't
25 	 23 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 convinced was
26 	 25 	 (S[pss]\NP)/S[em] 	 2 	 that convinced
29 	 27 	 NP[nb]/N 	 1 	 acquisition the
29 	 28 	 N/N 	 1 	 acquisition proposed
29 	 30 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 acquisition would
29 	 31 	 (S[b]\NP)/PP 	 1 	 acquisition be <XB>
30 	 26 	 S[em]/S[dcl] 	 1 	 would that
31 	 30 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 be would
32 	 31 	 (S[b]\NP)/PP 	 2 	 of be
34 	 32 	 PP/NP 	 1 	 benefit of
34 	 33 	 N/N 	 1 	 benefit net
34 	 35 	 (NP\NP)/NP 	 1 	 benefit to
36 	 35 	 (NP\NP)/NP 	 2 	 Canada to
<\s>
<s id="wsj_1938.9"> 16
1 	 0 	 N/N 	 1 	 officials Merieux
1 	 2 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 officials are
1 	 3 	 (S[pss]\NP)/(S[to]\NP) 	 1 	 officials expected <XB>
1 	 5 	 (S[b]\NP)/PP 	 1 	 officials meet <XB>
1 	 13 	 (S[b]\NP)/NP 	 1 	 officials discuss <XB>
3 	 2 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 expected are
4 	 3 	 (S[pss]\NP)/(S[to]\NP) 	 2 	 to expected
5 	 4 	 (S[to]\NP)/(S[b]\NP) 	 2 	 meet to
5 	 9 	 ((S\NP)\(S\NP))/NP 	 2 	 meet in
5 	 11 	 (S\NP)\(S\NP) 	 2 	 meet today
6 	 5 	 (S[b]\NP)/PP 	 2 	 with meet
8 	 6 	 PP/NP 	 1 	 officials with
8 	 7 	 N/N 	 1 	 officials federal
10 	 9 	 ((S\NP)\(S\NP))/NP 	 3 	 Ottawa in
13 	 12 	 (S[to]\NP)/(S[b]\NP) 	 2 	 discuss to
15 	 13 	 (S[b]\NP)/NP 	 2 	 decision discuss
15 	 14 	 NP[nb]/N 	 1 	 decision the
<\s>
